Wide Ranks

ALVOW

Alvotech Warrant

2.72

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 4399.70 %
Current Ratio 0.24 Trailing PE 0.0000 Earnings Growth -69.60 %
Profit Margins -200.30 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins -200.30 % Operating Margins 46.22 %
Balance Sheet
Total Cash 10 M Total Cash Per Share 0.0390 Total Debt 1 B
Total Debt To Equity Current Ratio 0.24 Book Value Per Share -3.50
All Measures
Message Board Id finmb_693209405 City Luxembourg City Uuid f86480d9-d284-3946-818e-48c78126a8cd
Previous Close 2.90 Book Value -3.50 Beta -0.0970
Total Debt 1 B Volume 13117 Fifty Two Week Low 2.72
Total Cash Per Share 0.0390 Total Revenue 308 M Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins 46.22 % Net Income To Common -618380992
Trailing Peg Ratio None Total Cash 10 M Revenue Per Share 1.28
Ebitda Margins -33.87 % Trailing PE 0.0000 Regular Market Previous Close 2.90
Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000 Open 3.03
Free Cashflow -287744736 Dividend Yield 0.00 % Return On Assets -0.0761
Time Zone Short Name EST Day Low 2.72 Address1 9, Rue de Bitbourg
Target High Price 0.0000 Price Hint 4 Website https://www.alvotech.com
Forward Eps 0.0000 Earnings Quarterly Growth -65.50 % Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 13.20 % Is_sp_500 False
Regular Market Day High 3.03 Profit Margins -200.30 % Fifty Two Week High 3.03
Day High 3.03 Regular Market Open 3.03 Industry Key drug-manufacturers-specialty-generic
Earnings Growth -69.60 % Revenue Growth 4399.70 % Operating Cashflow -310183008
Currency USD Time Zone Full Name America/New_York Is_nasdaq_100 False
Market Cap 0.0000 Zip 1273 Quote Type EQUITY
Industry Drug Manufacturers - Specialty & Generic Long Name Alvotech Regular Market Day Low 2.72
Current Price 2.72 Financial Currency USD Current Ratio 0.24
Gross Margins 48.79 % Industry Disp Drug Manufacturers - Specialty & Generic Country Luxembourg
Float Shares 98 M Forward PE 0.0000 Regular Market Volume 13117
Ebitda -104551000 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.

It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer.

The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.

In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product.

Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.